Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life
- PMID: 24178797
- DOI: 10.1210/jc.2013-1768
Penetrance of functioning and nonfunctioning pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 in the second decade of life
Abstract
Context: Data are scarce on the penetrance of multiple endocrine neoplasia type 1 (MEN1)-related nonfunctioning pancreatic neuroendocrine tumors (NF-PETs) and insulinomas in young MEN1 patients. A potential positive correlation between tumor size and malignancy (2-3 cm, 18%; >3 cm, 43%) has greatly influenced the management of MEN1 adults with NF-PETs.
Objective: The aim of the study was to estimate the penetrance of NF-PETs, insulinomas, and gastrinomas in young MEN1 carriers.
Design: The data were obtained from a screening program (1996-2012) involving 113 MEN1 patients in a tertiary academic reference center.
Patients: Nineteen MEN1 patients (aged 12-20 y; 16 patients aged 15-20 y and 3 patients aged 12-14 y) were screened for NF-PETs, insulinomas, and gastrinomas.
Methods: Magnetic resonance imaging/computed tomography and endoscopic ultrasound (EUS) were performed on 10 MEN1 carriers, magnetic resonance imaging/computed tomography was performed on five patients, and four other patients underwent an EUS.
Results: The overall penetrance of PETs during the second decade of life was 42% (8 of 19). All eight PET patients had NF-PETs, and half of those tumors were multicentric. One-fifth of the screened patients (21%; 4 of 19) harbored at least one large tumor (>2.0 cm). Insulinoma was detected in two NF-PET patients (11%) at the initial screening; gastrinoma was not present in any cases. Six of the 11 (54%) screened patients aged 15-20 years who underwent an EUS had NF-PETs. Potential false-positive EUS results were excluded based on EUS-guided biopsy results, the reproducibility of the NF-PET findings, or the observation of increased tumor size during follow-up. Distal pancreatectomy and the nodule enucleation of pancreatic head tumors were conducted on three patients with large tumors (>2.0 cm; T2N0M0) that were classified as grade 1 neuroendocrine tumors (Ki-67<2%).
Conclusions: Our data demonstrated high penetrance of NF-PETs in 15- to 20-year-old MEN1 patients. The high percentage of the patients presenting consensus criteria for surgery for NF-PET alone or NF-PET/insulinoma suggests a potential benefit for the periodic surveillance of these tumors in this age group.
Similar articles
-
Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain.J Clin Endocrinol Metab. 2014 Nov;99(11):E2387-91. doi: 10.1210/jc.2013-4432. Epub 2014 Sep 11. J Clin Endocrinol Metab. 2014. PMID: 25210877
-
Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?Surgery. 2000 Dec;128(6):958-66. doi: 10.1067/msy.2000.109727. Surgery. 2000. PMID: 11114630
-
Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1.Neuroendocrinology. 2013;98(4):290-8. doi: 10.1159/000357779. Epub 2013 Dec 17. Neuroendocrinology. 2013. PMID: 24356648
-
Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis.Endocr Relat Cancer. 2014 May 6;21(3):R121-42. doi: 10.1530/ERC-13-0482. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24389729 Review.
-
Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1).Minerva Endocrinol. 2013 Mar;38(1):17-28. Minerva Endocrinol. 2013. PMID: 23435440 Review.
Cited by
-
Questions and Controversies About Parathyroid Pathophysiology in Children With Multiple Endocrine Neoplasia Type 1.Front Endocrinol (Lausanne). 2018 Jul 17;9:359. doi: 10.3389/fendo.2018.00359. eCollection 2018. Front Endocrinol (Lausanne). 2018. PMID: 30065698 Free PMC article. No abstract available.
-
Clinical aspects of multiple endocrine neoplasia type 1.Nat Rev Endocrinol. 2021 Apr;17(4):207-224. doi: 10.1038/s41574-021-00468-3. Epub 2021 Feb 9. Nat Rev Endocrinol. 2021. PMID: 33564173 Review.
-
Surgery for multiple endocrine neoplasia type 1-related insulinoma: long-term outcomes in a large international cohort.Br J Surg. 2020 Oct;107(11):1489-1499. doi: 10.1002/bjs.11632. Epub 2020 Apr 30. Br J Surg. 2020. PMID: 32352164 Free PMC article.
-
Long-term Follow-up of MEN1 Patients Who Do Not Have Initial Surgery for Small ≤2 cm Nonfunctioning Pancreatic Neuroendocrine Tumors, an AFCE and GTE Study: Association Francophone de Chirurgie Endocrinienne & Groupe d'Etude des Tumeurs Endocrines.Ann Surg. 2018 Jul;268(1):158-164. doi: 10.1097/SLA.0000000000002191. Ann Surg. 2018. PMID: 28263205 Free PMC article. Clinical Trial.
-
The LARO-MEN1 study: a longitudinal clinical experience with octreotide Long-Acting Release in patients with Multiple Endocrine Neoplasia type 1 Syndrome.Clin Cases Miner Bone Metab. 2017 May-Aug;14(2):123-130. doi: 10.11138/ccmbm/2017.14.1.123. Epub 2017 Oct 25. Clin Cases Miner Bone Metab. 2017. PMID: 29263719 Free PMC article.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical